Loading...
01/11 11:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. Financial performance shows a significant net loss due to impairment, but cost-saving measures are in place. Product development is promising with positive feedback on XPro, but faces delays and dependence on partnerships. Market strategy is cautious, focusing on rare diseases. Cash reserves are adequate for the near term. Q&A highlights potential partnerships post-FDA meeting, but uncertainties remain. Overall, the sentiment balances out, leading to a neutral rating, with no strong catalysts for a significant stock price movement in the short term.
Net loss attributable to common stockholders Approximately $24.5 million for the quarter ended June 30, 2025, compared with approximately $9.7 million for the comparable period in 2024. The increase is due to impairment of acquired in-process research and development intangible assets.
Research and development expense Approximately $5.8 million for the quarter ended June 30, 2025, compared with approximately $7.1 million for the comparable period in 2024. The decrease is attributed to cost management and reduced spending in certain areas.
General and administrative expenses Approximately $2.3 million for the quarter ended June 30, 2025, compared with approximately $2.8 million for the comparable period in 2024. The decrease is due to cost-saving measures.
Impairment of acquired in-process research and development intangible assets $16.5 million for the quarter ended June 30, 2025, compared with $0 during the comparable period in 2024. This impairment is due to the conservative approach taken after the release of Phase II MINDFuL data and halting immediate plans for XPro development.
Cash and cash equivalents Approximately $33.4 million as of June 30, 2025. This is expected to fund operations into Q3 of 2026.
XPro Phase II MINDFuL trial: The trial confirmed that Alzheimer's patients with two or more biomarkers of inflammation are optimal candidates for XPro. The drug showed potential as a first-in-class treatment for Alzheimer's with elevated inflammation levels, representing 40%-60% of cases. The company is exploring strategic partnerships and rare disease pathways to accelerate market access.
CORDStrom: Focused on securing approval in the U.K. and U.S. for Recessive Dystrophic Epidermolysis Bullosa (RDEB) by mid-2026. The product has potential applications beyond RDEB, including other forms of epidermolysis bullosa and osteoarthritis. The company is also exploring genetic modifications for targeted treatments.
INKmune: Phase I/II program near completion, showing safety and immunologic benefits. Plans to explore trials in earlier-stage diseases to optimize its potential.
Strategic partnerships for XPro: Preliminary discussions with potential partners to advance XPro, targeting Alzheimer's patients with high inflammation.
CORDStrom market expansion: Potential to expand applications beyond RDEB to other forms of epidermolysis bullosa and osteoarthritis.
Financials: Net loss for Q2 2025 was $24.5 million, up from $9.7 million in Q2 2024. Cash and equivalents stand at $33.4 million, sufficient to fund operations into Q3 2026.
Leadership changes: David Moss appointed as CEO, succeeding RJ Tesi, who retired. Cory Ellspermann named Interim CFO.
XPro development strategy: Halted immediate plans for Phase III Alzheimer's trials due to high costs, focusing on partnerships and rare disease pathways.
CORDStrom development strategy: Aggressively pursuing regulatory approvals in the U.K. and U.S. by mid-2026, with plans for broader applications.
Phase II MINDFuL trial results: The trial did not meet its primary endpoint in the overall population, raising concerns about the drug's efficacy in broader Alzheimer's patient groups. Additionally, the placebo group did not decline, complicating the ability to measure XPro's effectiveness.
Strategic partnerships for XPro: Advancing to the next phase of XPro development will require substantial investment in manufacturing and clinical trials. The company has not yet secured strategic partnerships, which poses a risk to the program's progression.
Financial constraints: The company reported a net loss of $24.5 million for Q2 2025 and has cash reserves sufficient to fund operations only until Q3 2026. This financial limitation could impact the ability to advance multiple programs simultaneously.
Regulatory and approval timelines: The company faces aggressive timelines for regulatory submissions, such as the CORDStrom marketing authorization application and biologics licensing application by mid-2026. Delays or failures in meeting these timelines could hinder progress.
Market competition and differentiation: XPro's modest effect sizes and failure to meet primary endpoints in broader populations may limit its competitive edge against existing Alzheimer's treatments. Additionally, the absence of amyloid-related imaging abnormalities (ARIA) is a positive but may not be enough to differentiate the drug significantly.
Focus on rare diseases: The decision to pivot XPro's focus to rare diseases for faster market entry could limit its broader market potential and revenue opportunities.
INKmune trial results: The INKmune Phase I/II trial showed limited impact on disease burden in metastatic prostate cancer, raising questions about its efficacy in late-stage diseases. The company plans to shift focus to earlier-stage diseases, which may require additional time and resources.
Dependence on external funding and partnerships: The company’s ability to fully realize the potential of its platforms like CORDStrom and INKmune depends on securing non-dilutive funding or strategic partnerships, which are not guaranteed.
XPro Program: The company plans to advance XPro to Phase III trials, targeting Alzheimer's patients with high inflammation levels. They are preparing a briefing book for an end-of-Phase-II meeting with the FDA, expected by the end of 2025. They are also exploring strategic partnerships to support the program's advancement and considering applying for breakthrough therapy designation to expedite the process. Additionally, they are investigating shorter pathways to market, including rare disease indications, to maximize impact and accelerate patient access.
CORDStrom Program: The company aims to file for approval in the U.K. and U.S. for Recessive Dystrophic Epidermolysis Bullosa (RDEB) by mid-2026. They are also exploring the potential of CORDStrom for other forms of epidermolysis bullosa and additional indications, depending on available capital. Strategic partnerships or non-dilutive funding may be pursued to fully realize CORDStrom's value.
INKmune Program: The company plans to explore a trial focused on earlier-stage disease to optimize INKmune's potential, following the completion of the Phase I/II program. They are also working on developing manufacturing data to support commercial development and reduce costs.
Financial Guidance: The company has cash and cash equivalents of approximately $33.4 million as of June 30, 2025, which is expected to fund operations into Q3 of 2026. They are seeking strategic partnerships to support the advancement of their programs.
The selected topic was not discussed during the call.
The earnings call presents a mixed sentiment. Positive aspects include strong generative AI revenue growth and successful commerce bookings. However, the renegotiated Salesforce contract and negative cash flow are concerns. The Q&A reveals some uncertainties, such as delayed deals and the impact of the Salesforce contract on guidance. Overall, these factors balance each other, leading to a neutral sentiment. Without market cap data, the stock's reaction is uncertain, but the mixed signals suggest limited short-term movement.
The earnings call reveals several negative factors: a delay in the XPro FDA meeting, limited efficacy in the INKmune trial, and cautious partnership progress. While financial losses decreased and cash runway extends to Q4 2026, the need for additional financing looms. The Q&A session highlights uncertainties and management's reluctance to provide detailed guidance. These elements, combined with the lack of a new partnership announcement or strong guidance, suggest a negative stock price movement in the short term.
The earnings call presents a mixed picture. Financial performance shows a significant net loss due to impairment, but cost-saving measures are in place. Product development is promising with positive feedback on XPro, but faces delays and dependence on partnerships. Market strategy is cautious, focusing on rare diseases. Cash reserves are adequate for the near term. Q&A highlights potential partnerships post-FDA meeting, but uncertainties remain. Overall, the sentiment balances out, leading to a neutral rating, with no strong catalysts for a significant stock price movement in the short term.
The earnings call highlights several concerns: regulatory challenges, financial sustainability issues, and market competition. The Q&A section reveals management's reluctance to provide clear timelines or metrics, which may unsettle investors. The net loss and limited cash reserves further exacerbate financial worries. While there is potential excitement for new therapies, the overall sentiment leans negative due to uncertainties and lack of strong positive catalysts.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
